(1)The position and leading situation at the international, national, and provincial of companies' innovations passing appraisal (including new products, new technologies, new processes, new equipment, etc.):

Zhangqiu municipal technology center in 2004、Jinan municipal technical center in 2005. In recent years, the annual technology development costs have been increasing by 15 to 2 million yuan a year.

(2)Our company establishes close co-operation With Shanghai Polytechnic University, Tsinghua University, Jinan University, Shandong Medical Instrument Institute, Shandong Institute of Pharmaceutical Industry, including projects and products, technology transfer and cooperation, and personnel exchanges and training.

(3)Enterprise owns patented technology and product independent intellectual property rights, with production rate of 30%.

(4)Results science and technology achieving:

we have developed new products 10 species, of which eight kinds of raw material medicine (Ribavirin, Adenosine Triphosphate Disodium, Buflomedil Hydrochloride, Adenosine Cyclophosphate, Pantoprazole Sodium, Nateglinide, Terbinafine Hydrochloride, Nicergoline), two kinds of preparations (Oxymatrine Films, Adenosine Triphosphate Disodium tablets). We have obtained approval number of Omeprazole Enteric-coated Capsules.

Adapting to market demand, highlighting extension of the industry chain , that reduces the enterprise's investment risk and enhances the strength and profitability of the enterprise.